A 10% increase in LAMV in the vaccine mix was associated with a 23.2% decrease in throughput (SE 0.7; p < 0.01) (Table 2).
We found that a higher proportion of LAMV among vaccines administered and higher proportion of clinical staff among all personnel were associated with a reduction in throughput of vaccine.
POD, point of distribution; throughput, average vaccine doses administered per hour per POD event; vaccine mix, percentage of live-attenuated monovalent vaccine (LAMV); clinical staff time, percentage of clinical staff hours; queue length, average number of patients in queue outside PODs per hour per event; PODs same day, number of POD events held on the same day.
The first doses of H1N1 LAMV became available to the public in the United States on October 5, and H1N1 MIV became available the following week.
During October 5-November 20, a total of 46.2 million doses of H1N1 vaccines (11.3 million LAMV and 34.9 million MIV doses) and 98.9 million doses of seasonal influenza vaccines were distributed to U.S states and territories.
VAERS received 13 reports of deaths occurring after receipt of H1N1 vaccine; three deaths occurred after receipt of LAMV and 10 after receipt of MIV (Table 2).